Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 45

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 45
---
 as “patent trolls,” purchase patents and other intellectual property assets for the purpose
of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or “invitations
to license,” or may be the subject of claims that our products and business operations infringe or violate the intellectual property
rights of others. The defense of these matters can be time consuming, costly to defend in litigation, divert management’s attention
and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments.

If we fail to execute invention assignment agreements with our employees and contractors involved in the development of intellectual property or are unable to protect the confidentiality of our trade secrets, the value of our products and our business and competitive position could be harmed.

In addition to patent
protection, we also rely on protection of copyright, trade secrets, know-how and confidential and proprietary information. We
generally enter into confidentiality and invention assignment agreements with our employees, consultants and third parties upon
their commencement of a relationship with us. However, we may not enter into such agreements with all employees, consultants and
third parties who have been involved in the development of our intellectual property. In addition, these agreements may not provide
meaningful protection against the unauthorized use or disclosure of our trade secrets or other confidential information, and
adequate remedies may not exist if unauthorized use or disclosure were to occur. The exposure of our trade secrets and other
proprietary information would impair our competitive advantages and could have a material adverse effect on our business, financial
condition and results of operations. In particular, a failure to protect our proprietary rights may allow competitors to copy our
products and procedures, which could adversely affect our pricing and market share. Further, other parties may independently develop
substantially equivalent know-how and technology.

<div align='center'>31</div>

In addition to contractual
measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological
security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party
with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee
or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct
may not provide an adequate remedy to protect our interests fully. Unauthorized parties may also attempt to copy or reverse engineer certain
aspects of our